Quotient Ltd. (NASDAQ:QTNT) reached a new 52-week low on Friday . The company traded as low as $5.67 and last traded at $6.06, with a volume of 643,835 shares. The stock had previously closed at $7.50.

A number of research firms have recently weighed in on QTNT. Jefferies Group reaffirmed a “buy” rating and set a $28.00 price target on shares of Quotient in a research note on Wednesday, June 1st. Zacks Investment Research downgraded Quotient from a “hold” rating to a “sell” rating in a research note on Thursday, June 9th.

The company’s market cap is $83.38 million. The company’s 50-day moving average price is $8.21 and its 200 day moving average price is $9.36.

Quotient (NASDAQ:QTNT) last announced its quarterly earnings data on Monday, May 23rd. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. The company had revenue of $5.05 million for the quarter. On average, equities research analysts expect that Quotient Ltd. will post ($2.20) earnings per share for the current year.

In other Quotient news, President Jeremy Stackawitz sold 15,000 shares of the business’s stock in a transaction dated Thursday, June 9th. The stock was sold at an average price of $10.00, for a total value of $150,000.00. Following the completion of the transaction, the president now directly owns 127,741 shares of the company’s stock, valued at $1,277,410. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen Unger sold 8,516 shares of the business’s stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $10.49, for a total value of $89,332.84. Following the completion of the transaction, the chief financial officer now directly owns 21,497 shares of the company’s stock, valued at $225,503.53. The disclosure for this sale can be found here.

Quotient Limited is a commercial-stage diagnostics company. The Company is focused on blood grouping and serological disease screening. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody identification.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.